Jeff Min is a Respiratory physician affiliated with GlaxoSmithKline. OpenAlex indexes 43 publications with 617 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- kaleo, Inc.Program year20215 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2021–2021 per NIH RePORTER. The latest:
- Longitudinal effect of insulin resistance on right ventricular function
University of Pennsylvania
FY2021$20,895F32HL160107
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical Trials
American Journal of Respiratory and Critical Care Medicine
2026 - Mepolizumab Improves Exacerbation Outcomes in Patients with COPD with Type 2 Inflammation and Variable Eosinophil Patterns
Journal of Allergy and Clinical Immunology
2026 - Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
New England Journal of Medicine
2025 - Mepolizumab is Efficacious in Patients With Chronic Obstructive Pulmonary Disease Regardless of Investigator-Assessed Chronic Bronchitis and/or Emphysema: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial
American Journal of Respiratory and Critical Care Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Anil Panackal, MD, SM, FACP
GlaxoSmithKline
Paul Jones
GlaxoSmithKline
Laurence Collette
GlaxoSmithKline
Peter Hugo Howarth
GlaxoSmithKline
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”